NYSE: ABT
Abbott Laboratories is a global healthcare company with a diversified portfolio spanning four major segments: Medical Devices (including electrophysiology, rhythm management, heart failure, vascular, structural heart, neuromodulation, and diabetes care with its FreeStyle Libre continuous glucose monitoring platform), Diagnostics (core laboratory diagnostics, rapid and molecular diagnostics, and cancer diagnostics following the 2026 acquisition of Exact Sciences and its Cologuard colorectal cancer screening platform), Nutrition (pediatric and adult nutritional products sold globally), and Established Pharmaceuticals (branded generic medicines sold primarily in key emerging markets across Latin America, Asia Pacific, and other international regions). The company employs approximately 122,000 people and serves customers in more than 160 countries. Abbott's medical devices business accounts for the largest share of revenue, with continuous glucose monitors and electrophysiology products among its fastest-growing product lines. Updated
A single July 14 rotation out of healthcare and into AI silicon: the Abbott sale was the largest leg of the three, funding smaller buys in AMD and Broadcom. The filing landed 35 days later, as Congress debates limiting lawmaker stock trading.
Same quarter, as of Jun 30, 2026 · disclosed Aug 14, 2026 · ~45 days stale — a disclosure disagreement, not a live trade.
Steve Cohen's Point72 opened a new Abbott position and Two Sigma added to a $737 million stake in the June quarter, the same three months Lee Ainslie's Maverick Capital sold out entirely. Mason Hawkins also put Southeastern behind it, with everything disclosed August 14 as quarter-end snapshots.
One leg of a Ways and Means Republican's municipal bond buying sat undisclosed for 391 days, past the 45-day filing window, just as the House debates restricting lawmaker trading. The same lawmaker sold three consumer and healthcare positions on a single July day and moved the money into munis.
Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising…
Altria (NYSE:MO | MO Price Prediction) sends its latest quarterly check of $1.11 per share to shareholders on October 9, 2026. The prior rate was $1.06, so the raise works out to…
AbbVie investors who bought on headline-grabbing drug approvals consistently trailed those who bought during fear and uncertainty. The calendar of milestones reveals a counterintuitive pattern about when good news becomes a trap.
Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why…
Pre-Market Stock Futures: Futures are trading higher as we head into the first Friday of the fourth quarter of 2026. Investors rode a stock market rollercoaster Thursday as major indices moved back…
A secretary at an Illinois pharmaceutical company made a single, unremarkable stock purchase in 1935 and then did almost nothing for the next 75 years. What her college discovered when she died…
AJ Tiarsmith Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One…
Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons…
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made…
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it…
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly…
SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line…
Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the…
JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter…
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.
Abbott Laboratories is a global healthcare company with a diversified portfolio spanning four major segments: Medical Devices (including electrophysiology, rhythm management, heart failure, vascular, structural heart, neuromodulation, and diabetes care with its FreeStyle Libre continuous glucose monitoring platform)…
24/7 Wall St.'s 12-month price target for ABT is $116.53, rated Buy. The Wall Street consensus target is $120.74. ABT price prediction →
